Multi-Cancer Early Detection Testing Market (2033): Galleri Test, CancerSEEK & Liquid Biopsy Growth in United States Expansion

DataM Intelligence has released a new research report titled "Multi-Cancer Early Detection Testing Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Multi-Cancer Early Detection Testing market.

Download Sample Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/multi-cancer-early-detection-testing-market?sindhuri

Recent Key Developments - United States & North America
✅ September 2026: FDA advisory review moved MCED testing closer to a potential regulated screening pathway. The FDA's Molecular and Clinical Genetics Devices Panel reviewed GRAIL's PMA application for the Galleri multi-cancer early detection test on September 23. The panel voted 7-2 that the benefits outweigh the risks, unanimously supported safety, and voted 6-4 in support of effectiveness. The recommendation is non-binding, so the FDA's final decision remains separate from the committee vote.

✅ September 2026: Large-scale clinical evidence is reshaping the discussion around MCED implementation. Results from the 35,000+ participant PATHFINDER 2 study were published in Nature Medicine, providing detailed evidence on Galleri's performance and safety in adults aged 50 and older. The publication adds clinical evidence at a scale more closely aligned with the intended screening population rather than relying only on smaller validation cohorts.

✅ July 2026: Freenome entered the public market with capital earmarked for commercial cancer-screening infrastructure. Freenome completed its business combination and began trading on Nasdaq under FRNM, with more than $300 million in gross proceeds from the transaction. The company said the funding would support its blood-based cancer-screening portfolio, AI/ML-enabled multiomics platform, and commercial infrastructure, highlighting the shift from assay development toward broader clinical commercialization.

Recent Key Developments - Japan & Asia-Pacific
✅ July 2026: Abbott launched its Cancerguard MCED blood test in Japan, creating its first overseas commercial MCED market. The test analyzes biomarkers associated with 50 cancer types from a single blood sample and is being offered through partner medical institutions. Japan therefore became Abbott's first market outside the United States where the company commercially provides its MCED test.

✅ July 2026: Japanese cancer-screening providers are testing new consumer-oriented routes around routine health checks. SalivaTech promoted its SalivaChecker cancer-risk testing service through a July-August campaign tied to Japan's annual health-check and human-dock culture, positioning the test as an additional check between routine examinations rather than as a replacement for established screening. This points to a broader Japanese market model in which non-invasive cancer-risk testing is being attached to existing preventive-health workflows.

✅ September 2026: China expanded infrastructure for data-driven opportunistic cancer screening. The National Cancer Center awarded a RMB 7.41 million project for cancer-screening data governance, model optimization, and screening-promotion applications. While not limited to MCED assays, the project is relevant to the emerging screening ecosystem because it focuses on the data and analytical infrastructure needed to deploy and optimize cancer-screening models at scale.

Recent Key Developments - Product & Technology Innovation
✅ September 2026: Multi-omics approaches are moving beyond conventional single-biomarker MCED models. A newly approved U.S. National Cancer Institute data-access project is evaluating a serum NMR-based multi-omics MCED assay, specifically examining analytical suitability and storage stability using pre-diagnostic PLCO specimens. The work reflects growing interest in combining multiple biological signals rather than relying on a single marker class.

✅ July 2026: Commercial MCED testing is increasingly combining different biomarker classes. Abbott's Cancerguard uses methylated DNA and protein biomarkers from a single blood sample, while newer research programs are examining combinations of genomic, epigenetic, protein, and other biological signals. This multi-signal approach is becoming an important technical direction for improving cancer-signal detection and tissue-of-origin prediction.

✅ September 2026: The NHS-Galleri results highlighted a critical technology-to-clinical-practice issue-early detection must translate into meaningful stage shifts. The first full NHS-Galleri results, published in September, found no overall difference in combined stage III/IV cancer diagnoses, although fewer of the most advanced cancers were diagnosed in the screened group. The findings are likely to keep clinical utility, follow-up pathways, and real-world outcomes at the center of MCED development rather than focusing only on laboratory sensitivity and specificity.

List of Key Players 2026:
GRAIL, Inc., Guardant Health, Exact Sciences Corporation, Burning Rock Biotech, Lucence Health and Foundation Medicine (Roche)

Company Evaluation
Leading multi-cancer early detection companies such as GRAIL, Guardant Health and Exact Sciences are strengthening their market presence through blood-based screening tests, liquid biopsy technologies, genomic analysis and AI-enabled biomarker detection.

Innovative companies such as Freenome, Burning Rock Biotech and Lucence Health are advancing multi-omics, AI-driven diagnostics and ctDNA-based liquid biopsy platforms, while clinical validation, regulatory approvals and testing accuracy remain key areas of evaluation.

Growth Forecast Projected 2026:
The Global Multi-Cancer Early Detection Testing Market is anticipated to grow at a considerable rate during the forecast period, between 2026 and 2033. The market was valued at approximately US$2.24 billion in 2025 and is projected to reach US$10.22 billion by 2033, expanding at a CAGR of 16.5% during the forecast period. Rising cancer prevalence, demand for non-invasive screening, advancements in liquid biopsy, next-generation sequencing and AI-driven diagnostics are expected to support market growth.

Get 20% Complimentary Customization Within the Report:
https://www.datamintelligence.com/customize/multi-cancer-early-detection-testing-market?sindhuri

M&A / Strategic Activity
Recent acquisitions, partnerships, and commercial developments shaping the Multi-Cancer Early Detection Testing Market:

Abbott - Acquisition of Exact Sciences and expansion into multi-cancer screening
Abbott completed its acquisition of Exact Sciences on March 23, 2026, bringing Cancerguard, Exact Sciences' multi-cancer early detection blood test, into Abbott's diagnostics portfolio. Abbott is combining Exact Sciences' cancer-screening and molecular-diagnostics capabilities with its global diagnostics infrastructure, creating a broader commercial platform spanning early detection, treatment guidance, and recurrence monitoring.

GRAIL - Samsung strategic collaboration and international commercialization
GRAIL and Samsung established a strategic collaboration to explore combining Galleri with Samsung's AI, digital-health platform, and device ecosystem. Samsung-affiliated entities subsequently invested $110 million in GRAIL in June 2026, with GRAIL identifying international expansion and regulatory approval as key uses of the investment.

GRAIL - Epic EHR integration for point-of-care ordering
In April 2026, GRAIL announced integration of Galleri into Epic Aura, allowing participating health systems to order the test and receive results through existing electronic health-record workflows. The integration is designed to make MCED testing part of routine clinical workflows rather than requiring a separate ordering and results-management process.

Guardant Health - Manulife partnership brings Shield MCD to Asia
Guardant Health launched its Shield Multi-Cancer Detection test in Hong Kong, Singapore, and the Philippines through a partnership with Manulife. Beginning in April 2026, eligible Manulife customers in these markets gained access to the methylation-based blood test, creating an insurer-supported route for commercial MCED access in Asia.

Freenome - Commercial infrastructure and strategic licensing
Freenome granted Exact Sciences exclusive U.S. rights to its blood-based colorectal cancer screening tests in a deal worth up to $885 million, tied to regulatory and screening-guideline milestones. Freenome retained rights connected with combining its technology with additional cancer-screening tests and continued developing a broader multi-cancer platform.

New Product/Test Launches & Deployments
Recent product launches and real-world deployments are moving MCED testing from research programs toward clinical and commercial use:

Exact Sciences / Abbott - Cancerguard commercial launch
Exact Sciences launched Cancerguard in September 2025 as a laboratory-developed MCED test priced at $689. Unlike tests relying on a single biomarker class, Cancerguard analyzes multiple biomarker classes and was made accessible nationally through Quest Diagnostics' 7,000 patient access sites. Abbott now owns and commercializes the product following completion of the Exact Sciences acquisition.

GRAIL - Galleri FDA regulatory transition
GRAIL submitted the final module of its FDA Premarket Approval application for Galleri in January 2026. On September 23, 2026, the FDA advisory committee voted in favor of approval of the Galleri MCED test, marking an important regulatory development for a test that has previously been offered as a laboratory-developed test.

Guardant Health - Shield MCD expansion across Asia
Guardant's Shield MCD moved beyond the U.S. market into Hong Kong, Singapore, and the Philippines in 2026. The test uses methylation-based cell-free DNA analysis and is designed to detect signals associated with 10 cancer types, including colorectal, lung, liver, pancreatic, ovarian, gastric, esophageal, breast, prostate, and bladder cancers.

GRAIL - Employer and health-plan access model
GRAIL expanded Galleri access through health-plan arrangements rather than relying solely on individual self-pay ordering. In July 2026, Priority Health became the first Michigan health plan to make Galleri available to its self-insured employer groups, building on its earlier Medicare Advantage coverage.

GRAIL - NHS-Galleri evidence reshapes deployment strategy
The first full NHS-Galleri trial results published in September 2026 reported no overall difference in the combined rate of stage III and IV cancers between the Galleri and control groups. The result adds an important evidence consideration as MCED developers move from analytical performance and cancer-signal detection toward demonstrating population-level screening benefit.

R&D & Technological Advancements
Multi-omics and multimodal biomarker analysis
MCED development is moving beyond single-signal detection toward combinations of biological signals. Exact Sciences' Cancerguard uses multiple biomarker classes, while Freenome continues developing AI/ML-enabled multiomics approaches that combine molecular information to improve early cancer detection.

Cell-free DNA methylation remains a major technical pathway
Methylation analysis continues to be central to several leading MCED approaches. Guardant's Shield MCD uses methylation-based cell-free DNA analysis, while academic research supported by the NCI is exploring more sensitive and cost-efficient cfDNA methylome sequencing approaches to address the challenge of detecting cancers at earlier stages.

Large-scale randomized evidence is becoming the key development hurdle
The NCI's Cancer Screening Research Network has shifted attention toward determining whether MCED testing actually improves cancer outcomes rather than simply demonstrating analytical accuracy. Its Vanguard Study is designed to enroll up to 24,000 participants and determine the feasibility of a larger randomized trial comparing MCD screening strategies with standard screening.

Assay performance is being tested independently across platforms
The NCI has conducted independent performance work using blinded reference specimens and selected ClearNote Health's Avantect and Guardant Health's Shield MCD for the Vanguard Study. This creates a more standardized pathway for comparing commercially developed assays before they move into much larger screening-outcome trials.

Research is targeting the early-stage sensitivity problem
Current research is increasingly focused on cancers that shed limited amounts of detectable biological material at early stages. NCI-funded work on cfDNA methylome sequencing specifically identifies unsatisfactory early-stage performance as a current limitation and is investigating higher-sensitivity sequencing approaches.

Clinical workflow integration is becoming part of product development
MCED companies are increasingly building ordering, results delivery, and follow-up into existing healthcare infrastructure. GRAIL's Epic integration is an example of this shift, allowing Galleri ordering and results management within established EHR workflows rather than creating a separate technology pathway for clinicians.

Purchase This Exclusive Report:
https://www.datamintelligence.com/buy-now-page?report=multi-cancer-early-detection-testing-market?sindhuri

Segments Covered in the Global Multi Cancer Early Detection Testing Market:
By Test Type
The market is segmented into Galleri Test, CancerSEEK, and others. Galleri Test accounts for a significant market share due to its ability to screen for multiple cancer types through a single blood test and growing interest in early cancer detection. CancerSEEK is witnessing increasing adoption driven by its multi-cancer detection capabilities and potential to identify cancer at earlier stages. Other tests are gaining traction through ongoing research, technological advancements, and the development of next-generation liquid biopsy and multi-cancer screening technologies.

By Cancer Type
The market is divided into breast cancer, colorectal cancer, lung cancer, blood cancer, prostate cancer, and others. Breast cancer represents a significant segment due to its high global prevalence and increasing emphasis on early diagnosis and screening. Colorectal cancer and lung cancer are witnessing strong demand for early detection technologies due to their substantial disease burden and the benefits of identifying cancer before advanced-stage progression. Blood cancer and prostate cancer applications are also expanding as researchers develop more sensitive and comprehensive multi-cancer detection approaches.

By End User
The market is segmented into hospitals & clinics, diagnostic laboratories, and academic & research institutes. Hospitals & clinics account for a significant market share due to increasing adoption of advanced cancer screening technologies and integration of early detection testing into clinical care pathways. Diagnostic laboratories are witnessing strong growth as demand increases for blood-based cancer screening, molecular diagnostics, and centralized testing services. Academic & research institutes are also contributing to market development through clinical studies, biomarker discovery, and validation of emerging multi-cancer detection technologies.

By Region
North America - 38% Share
North America leads the market due to high healthcare expenditure, strong adoption of advanced cancer diagnostics, increasing investment in liquid biopsy technologies, and growing awareness of early cancer detection across the United States and Canada.

Europe - 27% Share
Europe is driven by increasing cancer screening initiatives, supportive healthcare infrastructure, rising adoption of precision diagnostics, and growing research activities focused on multi-cancer early detection technologies across countries such as Germany, the UK, France, and Italy.

Asia-Pacific - 25% Share
Asia-Pacific is expanding rapidly due to the rising cancer burden, improving healthcare infrastructure, growing diagnostic capabilities, and increasing investments in advanced cancer screening technologies across China, Japan, South Korea, and India.

Contact Us -
Company Name: DataM Intelligence Contact
Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.